# ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

> **NCT00056537** · PHASE1 · COMPLETED · sponsor: **Active Biotech AB** · enrollment: 44 (actual)

## Conditions studied

- Non-Small-Cell Lung Carcinoma
- Renal Cell Carcinoma
- Pancreatic Cancer

## Interventions

- **DRUG:** ABR-217620

## Key facts

- **NCT ID:** NCT00056537
- **Lead sponsor:** Active Biotech AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056537, "ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00056537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*